131 related articles for article (PubMed ID: 37861452)
1. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
Nolan-Stevaux O; Li C; Liang L; Zhan J; Estrada J; Osgood T; Li F; Zhang H; Case R; Murawsky CM; Estes B; Moore GL; Bernett MJ; Muchhal U; Desjarlais JR; Staley BK; Stevens J; Cooke KS; Aeffner F; Thomas O; Stieglmaier J; Lee JL; Coxon A; Bailis JM
Cancer Discov; 2024 Jan; 14(1):90-103. PubMed ID: 37861452
[TBL] [Abstract][Full Text] [Related]
2. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Kelly WK; Danila DC; Lin CC; Lee JL; Matsubara N; Ward PJ; Armstrong AJ; Pook D; Kim M; Dorff TB; Fischer S; Lin YC; Horvath LG; Sumey C; Yang Z; Jurida G; Smith KM; Connarn JN; Penny HL; Stieglmaier J; Appleman LJ
Cancer Discov; 2024 Jan; 14(1):76-89. PubMed ID: 37861461
[TBL] [Abstract][Full Text] [Related]
3. The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.
Deegen P; Thomas O; Nolan-Stevaux O; Li S; Wahl J; Bogner P; Aeffner F; Friedrich M; Liao MZ; Matthes K; Rau D; Rattel B; Raum T; Kufer P; Coxon A; Bailis JM
Clin Cancer Res; 2021 May; 27(10):2928-2937. PubMed ID: 33504551
[TBL] [Abstract][Full Text] [Related]
4. Bispecific T-cell Engagers in Metastatic Castration-Resistant Prostate Cancer.
Hage Chehade C; Gebrael G; Agarwal N
Cancer Discov; 2024 Jan; 14(1):20-22. PubMed ID: 38213299
[TBL] [Abstract][Full Text] [Related]
5. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
Bhatia V; Kamat NV; Pariva TE; Wu LT; Tsao A; Sasaki K; Sun H; Javier G; Nutt S; Coleman I; Hitchcock L; Zhang A; Rudoy D; Gulati R; Patel RA; Roudier MP; True LD; Srivastava S; Morrissey CM; Haffner MC; Nelson PS; Priceman SJ; Ishihara J; Lee JK
Nat Commun; 2023 Apr; 14(1):2041. PubMed ID: 37041154
[TBL] [Abstract][Full Text] [Related]
6. Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.
Lin TY; Park JA; Long A; Guo HF; Cheung NV
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34497115
[TBL] [Abstract][Full Text] [Related]
7. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
8. MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Hernandez-Hoyos G; Sewell T; Bader R; Bannink J; Chenault RA; Daugherty M; Dasovich M; Fang H; Gottschalk R; Kumer J; Miller RE; Ravikumar P; Wiens J; Algate PA; Bienvenue D; McMahan CJ; Natarajan SK; Gross JA; Blankenship JW
Mol Cancer Ther; 2016 Sep; 15(9):2155-65. PubMed ID: 27406985
[TBL] [Abstract][Full Text] [Related]
9. Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using
Carrasquillo JA; Fine BM; Pandit-Taskar N; Larson SM; Fleming SE; Fox JJ; Cheal SM; O'Donoghue JA; Ruan S; Ragupathi G; Lyashchenko SK; Humm JL; Scher HI; Gönen M; Williams SP; Danila DC; Morris MJ
J Nucl Med; 2019 Nov; 60(11):1517-1523. PubMed ID: 31053681
[TBL] [Abstract][Full Text] [Related]
10. Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
Penny HL; Hainline K; Theoharis N; Wu B; Brandl C; Webhofer C; McComb M; Wittemer-Rump S; Koca G; Stienen S; Bargou RC; Hummel HD; Loidl W; Grüllich C; Eggert T; Tran B; Mytych DT
Front Immunol; 2023; 14():1261070. PubMed ID: 37942314
[TBL] [Abstract][Full Text] [Related]
11. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
Zorko NA; Ryan CJ
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):986-996. PubMed ID: 34035459
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Biodistribution of a [
O'Donoghue JA; Danila DC; Pandit-Taskar N; Beylergil V; Cheal SM; Fleming SE; Fox JJ; Ruan S; Zanzonico PB; Ragupathi G; Lyashchenko SK; Williams SP; Scher HI; Fine BM; Humm JL; Larson SM; Morris MJ; Carrasquillo JA
Mol Pharm; 2019 Jul; 16(7):3083-3090. PubMed ID: 31117485
[TBL] [Abstract][Full Text] [Related]
13. Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer.
Jin Y; Lorvik KB; Jin Y; Beck C; Sike A; Persiconi I; Kvaløy E; Saatcioglu F; Dunn C; Kyte JA
Mol Ther Oncolytics; 2022 Sep; 26():189-206. PubMed ID: 35860008
[TBL] [Abstract][Full Text] [Related]
14. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.
Palecki J; Bhasin A; Bernstein A; Mille PJ; Tester WJ; Kelly WK; Zarrabi KK
Cancer Biol Ther; 2024 Dec; 25(1):2356820. PubMed ID: 38801069
[TBL] [Abstract][Full Text] [Related]
15. Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers.
Jin Y; Dunn C; Persiconi I; Sike A; Skorstad G; Beck C; Kyte JA
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203757
[TBL] [Abstract][Full Text] [Related]
16. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII.
Sternjak A; Lee F; Thomas O; Balazs M; Wahl J; Lorenczewski G; Ullrich I; Muenz M; Rattel B; Bailis JM; Friedrich M
Mol Cancer Ther; 2021 May; 20(5):925-933. PubMed ID: 33632870
[TBL] [Abstract][Full Text] [Related]
18. Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer.
Danila DC; Szmulewitz RZ; Vaishampayan U; Higano CS; Baron AD; Gilbert HN; Brunstein F; Milojic-Blair M; Wang B; Kabbarah O; Mamounas M; Fine BM; Maslyar DJ; Ungewickell A; Scher HI
J Clin Oncol; 2019 Dec; 37(36):3518-3527. PubMed ID: 31689155
[TBL] [Abstract][Full Text] [Related]
19. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
20. STEAP1 is overexpressed in cancers: a promising therapeutic target.
Moreaux J; Kassambara A; Hose D; Klein B
Biochem Biophys Res Commun; 2012 Dec; 429(3-4):148-55. PubMed ID: 23142226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
